ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 153592" data-attributes="member: 13851"><p><strong>Context</strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>Can injectable testosterone undecanoate (TU) be administered effectively and acceptably by the subcutaneous route? </em></span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Objective</strong></p><p></p><p><em>To investigate the acceptability and pharmacokinetics (PK) of sc injection of TU.</em></p><p></p><p></p><p><strong>Design</strong></p><p></p><p><em>Randomized sequence, cross-over clinical study of sc vs im TU injections.</em></p><p></p><p></p><p><strong>Setting</strong></p><p></p><p><em>Ambulatory clinic of an academic Andrology centre.</em></p><p></p><p></p><p><strong>Participants</strong></p><p></p><p><em>Twenty men (11 hypogonadal, 9 transmen) who were long-term users of TU injections.</em></p><p></p><p></p><p><strong>Intervention</strong></p><p></p><p><em>Injection of 1000 mg TU (in 4 ml castor oil vehicle) by sc or im route.</em></p><p></p><p></p><p><strong>Main Outcome Measures</strong></p><p></p><p><em>Patient reported Pain, Acceptability and Preference scales. PK by measurement of serum testosterone, dihydrotestosterone (DHT) and estradiol (E2) concentrations with application of population PK methods and dried blood spot (DBS) sampling.</em></p><p></p><p></p><p></p><p><strong>Results</strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>Pain was greater after sc compared with im injection 24 hour (but not immediately) after injection but both routes were equally acceptable.</em></span></strong> <em><strong>Ultimately 11 preferred im, 6 preferred sc and 3 had no preference.</strong> <span style="color: rgb(44, 130, 201)"><strong>The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after sc vs im injection (8.0 vs 3.3 days) </strong></span><span style="color: rgb(26, 188, 156)"><strong>but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/ml) or mean resident time (183 vs 110 days). </strong></span><span style="color: rgb(251, 160, 38)"><strong>The PK of venous serum testosterone, DHT and E2 did not differ according to route of injection. </strong></span></em></p><p> <em><span style="color: rgb(251, 160, 38)"><strong></strong></span></em></p><p></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>We conclude that sc TU injection is acceptable but produces greater pain 24 hours after injection which may contribute to the overall majority preference for the im injection.</em></span></strong><em> <span style="color: rgb(251, 160, 38)"><strong>The PK of testosterone, DHT or E2 did not differ substantially between sc and im routes.</strong></span> <strong><span style="color: rgb(147, 101, 184)">Hence while further studies are required, the sc route represents an alternative to im injections without a need to change dose for men where im injection is not desired or recommended.</span></strong></em></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(147, 101, 184)"><em>We conclude that with clinic-based delivery sc injection of TU is effective with similar PK parameters to im TU so not requiring dose modification.</em></span></strong> <strong><em>It is acceptable but generally less preferable compared with im TU for men. Thereby sc TU injection constitutes an alternative delivery route in circumstances where im injection is not desired, feasible or recommended. <span style="color: rgb(184, 49, 47)">Despite causing slightly more injection site pain 24 hours after injection, sc injection was generally acceptable but not preferred over im injection by most participants in this study who were long-term satisfied users of im TU.</span> These preliminary findings indicate that sc injection may prove a viable alternative delivery route where required. Whether self-injection of either the 4ml or two 2ml injections is feasible or acceptable remains to be determined. </em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 153592, member: 13851"] [B]Context [COLOR=rgb(184, 49, 47)][I]Can injectable testosterone undecanoate (TU) be administered effectively and acceptably by the subcutaneous route? [/I][/COLOR] Objective[/B] [I]To investigate the acceptability and pharmacokinetics (PK) of sc injection of TU.[/I] [B]Design[/B] [I]Randomized sequence, cross-over clinical study of sc vs im TU injections.[/I] [B]Setting[/B] [I]Ambulatory clinic of an academic Andrology centre.[/I] [B]Participants[/B] [I]Twenty men (11 hypogonadal, 9 transmen) who were long-term users of TU injections.[/I] [B]Intervention[/B] [I]Injection of 1000 mg TU (in 4 ml castor oil vehicle) by sc or im route.[/I] [B]Main Outcome Measures[/B] [I]Patient reported Pain, Acceptability and Preference scales. PK by measurement of serum testosterone, dihydrotestosterone (DHT) and estradiol (E2) concentrations with application of population PK methods and dried blood spot (DBS) sampling.[/I] [B]Results [COLOR=rgb(184, 49, 47)][I]Pain was greater after sc compared with im injection 24 hour (but not immediately) after injection but both routes were equally acceptable.[/I][/COLOR][/B][COLOR=rgb(184, 49, 47)][I][B] [/B][/I][/COLOR][I][B]Ultimately 11 preferred im, 6 preferred sc and 3 had no preference.[/B] [COLOR=rgb(44, 130, 201)][B]The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after sc vs im injection (8.0 vs 3.3 days) [/B][/COLOR][COLOR=rgb(26, 188, 156)][B]but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/ml) or mean resident time (183 vs 110 days). [/B][/COLOR][COLOR=rgb(251, 160, 38)][B]The PK of venous serum testosterone, DHT and E2 did not differ according to route of injection. [/B][/COLOR][/I] [B]Conclusions [COLOR=rgb(184, 49, 47)][I]We conclude that sc TU injection is acceptable but produces greater pain 24 hours after injection which may contribute to the overall majority preference for the im injection.[/I][/COLOR][/B][I] [COLOR=rgb(251, 160, 38)][B]The PK of testosterone, DHT or E2 did not differ substantially between sc and im routes.[/B][/COLOR] [B][COLOR=rgb(147, 101, 184)]Hence while further studies are required, the sc route represents an alternative to im injections without a need to change dose for men where im injection is not desired or recommended.[/COLOR][/B][/I] [B][COLOR=rgb(147, 101, 184)][I]We conclude that with clinic-based delivery sc injection of TU is effective with similar PK parameters to im TU so not requiring dose modification.[/I][/COLOR][/B][I] [/I][B][I]It is acceptable but generally less preferable compared with im TU for men. Thereby sc TU injection constitutes an alternative delivery route in circumstances where im injection is not desired, feasible or recommended. [COLOR=rgb(184, 49, 47)]Despite causing slightly more injection site pain 24 hours after injection, sc injection was generally acceptable but not preferred over im injection by most participants in this study who were long-term satisfied users of im TU.[/COLOR] These preliminary findings indicate that sc injection may prove a viable alternative delivery route where required. Whether self-injection of either the 4ml or two 2ml injections is feasible or acceptable remains to be determined. [/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top